Johanna W. Wilmink

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Sil Kordes, Michaël Pollak, Aeilko H. Zwinderman et al. · The Lancet Oncology · 2015 · 372 citations

Placebo-controlled Phase 2, Oncology, Pancreatic Cancer +8

Radioprotection of <i>IDH1</i> -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Remco J. Molenaar, Dennis Botman, Myrthe A J Smits et al. · Cancer Research · 2015 · 142 citations

Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment

Stijn van Roessel, Eran van Veldhuisen, Sjors Klompmaker et al. · JAMA Oncology · 2020 · 131 citations · Full text

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

<i>IDH1/2</i> Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

Remco J. Molenaar, Tomas Radivoyevitch, Yasunobu Nagata et al. · Clinical Cancer Research · 2018 · 101 citations · Full text